No fee unless we recover compensation for your family Text size 833-4-ASBESTOS (833-427-2378) Free Case Review

Clinical Nuclear Medicine

Our medical research library holds 26 studies published in Clinical Nuclear Medicine (1980–2024). Each entry links to the study's record on PubMed and, where there is one, to the publisher's page and a free full text. 23 have an abstract, the authors' own summary as PubMed records it: open "Abstract" to read it. For 2 studies PubMed has no abstract for, we give the abstract printed in the article or, where there is none, a summary we wrote from it, each labeled as such.

You don't need the product names or old records. No fee unless we recover compensation for your family.

Call 833-4-ASBESTOS Request a review

About the journal

  • Publisher: Lippincott
  • Published: 1976 to the present, United States
  • Language: English
  • ISSN: 0363-9762 (print), 1536-0229 (electronic)
  • Its record in the NLM Catalog

2020s

  • Epithelial Malignant Pleural Mesothelioma Mimics Lymphoma on 18 F-FDG PET/MRI : A Case Report. T. Tian, H. Xie, M. Huang. 2024;49(4):359-360. Case report PubMed · Publisher

    Abstract

    Malignant pleural mesothelioma is a rare tumor with a poor prognosis. We describe a case of 55-year-old man without asbestos exposure history presenting with extensive lymph nodes with high 18 F-FDG uptake in PET/MRI but atypical pleural manifestations thereby being misdiagnosed for lymphoma. Pathological examination concludes for an epithelioid mesothelioma-associated lymph node metastasis. This case emphasizes that with the extensive lymph node abnormalities shown in PET imaging, in addition to the general consideration of lymphoma, it is still necessary to be vigilant about the possibility of mesothelioma and emphasizes the necessity of pathological examination.

    Copyright © 2024 Wolters Kluwer Health, Inc. All rights reserved.

  • 18F-FDG Uptake of Localized Malignant Peritoneal Mesothelioma. E. Kodama, T. Kodama, T. Ichikawa, et al. 2020;45(2):161-163. Case report PubMed · Publisher

    Abstract

    We present 2 cases of malignant peritoneal mesothelioma (MPM) characterized by a localized solid mass without ascites and showing F-FDG uptake. A 79-year-old man with a history of asbestos exposure suffered from an epithelioid MPM originating from the hepatoduodenal ligament with FDG uptake (SUVmax 16.8). Another 80-year-old man with esophageal cancer showed desmoplastic MPM of the small bowel mesentery with FDG uptake (SUVmax 4.0). Desmoplastic MPM is more aggressive and yields poorer prognosis compared with the epithelioid type. However, the present desmoplastic MPM case showed mild FDG uptake because of rich fibrosis.

  • 99mTc-HDP Bone Scintigraphy, SPECT/CT, and 18F-FDG PET/CT Diagnosis Imaging of Incidental Pleural Mesothelioma in a Patient With Biochemical Recurrences of Prostate Cancer: Is it Really a Coincidence?. P. Fernández-Rodríguez, J.J. Martín-Marcuartu, I. Acevedo Báñez, et al. 2020;45(3):e148-e150. Case report PubMed · Publisher

    Abstract

    We present the case of a 69-year-old man with history of prostate carcinoma treated with prostatectomy and subsequently with external beam radiotherapy and hormone therapy because of biochemical recurrences. More than 10 years after the diagnosis, follow-up Tc-HDP bone scans and SPECT/CT images demonstrated an incidental diagnosis of osteoblastic pleural plaques that quickly evolve to mesothelioma. PET/CT achieved the definitive diagnosis by guiding the biopsy to the highest and most accessible focus of glucidic hypermetabolism. Our case report raises the association between prostate cancer patients treated with external beam radiotherapy and the development of pleural mesothelioma despite having no history of exposure to asbestos.

  • A Case of Localized Malignant Peritoneal Mesothelioma Evaluated by 18F-FDG PET/CT. T. Xu, J. Hu, X. Zhang, et al. 2020;45(11):890-891. Case report PubMed · Publisher

    Abstract

    Localized malignant mesothelioma is rare. The prognosis is generally more favorable for this condition than for diffuse malignant mesothelioma. An elderly woman recently complained of abdominal pain, fever, and weight loss. She had no history of asbestos exposure. Her serum CEA level was elevated. Plain CT revealed a mass under the left diaphragm, with liquefaction and necrosis. A contrast-enhanced scan showed circular enhancement of the mass. A subsequent biopsy of the mass revealed a poorly differentiated carcinoma. PET/CT showed a significant FDG-avid subphrenic mass without any indications of metastasis. Postoperative pathological and immunohistochemical examination confirmed a case of malignant mesothelioma.

  • A Case of Localized Malignant Peritoneal Mesothelioma With Lung Cancer Detected by 18F-FDG PET/CT. S. Kobayashi Shimizu, T. Okamura, K. Koyama, et al. 2020;45(10):795-797. Case report PubMed · Publisher

    Abstract

    A 62-year-old woman was referred for cough and lower abdominal pain. F-FDG PET/CT showed strong uptake not only in the left lung mass and hilar and mediastinal lymph nodes, but also a huge lower abdominal mass. All lesions were initially thought to be multiple metastases because bronchial biopsy of the lung mass showed poorly differentiated adenocarcinoma. However, the abdominal mass was found to be malignant peritoneal mesothelioma after surgical resection. It was difficult to diagnose this case correctly before resection because localized malignant peritoneal mesothelioma is rare.

2010s

2000s

1990s

  • Uptake of In-111 pentetreotide by pleural plaques. M. Lonneux, F. Jamar, N. Leners, et al. 1998;23(5):298-301. Case report PubMed · Publisher

    Abstract

    Somatostatin receptor imaging with In-111 pentetreotide has been validated for the diagnosis and staging of chest tumors with neuroendocrine differentiation such as bronchial carcinoid and small cell lung cancer. In-111 pentetreotide uptake is not specific for neuroendocrine tumors because somatostatin receptors are also expressed by white blood cells, leading to the in vivo visualization sites of infection sites or active inflammation. Pleural plaques may be due to asbestos exposure or tuberculosis. Presented here are three cases of In-111 pentetreotide uptake in pleural plaques. This uptake by benign lesions may be misleading in the diagnostic work-up of patients with lung tumors.

  • P-32 bremsstrahlung SPECT helps assess intracavitary therapy. B. Petri, R. Nance, J. Hanada, et al. 1992;17(9):709-10. Case report PubMed · Publisher

    Abstract

    A patient underwent intracavitary P-32 chromic phosphate therapy for a chest tumor. Tc-99m sulfur colloid instilled before the P-32 demonstrated uniform distribution of activity throughout the right pleural space, and the P-32 was immediately administered. Ten days later, SPECT imaging using bremsstrahlung radiation of the P-32 showed an unexpected loculation of the P-32. A subsequent chest CT scan demonstrated pleural infolding and fluid localization in the same area as the P-32, indicating that the bremsstrahlung SPECT study had, in fact, documented the final localization of the P-32, which was unexpected and different from the initial localization. The procedure used in this case may be of value in documenting the ultimate distribution of intracavitary P-32.

1980s

Browse every journal in the library or the library by type of article, or return to medical research.

Cite this page

“Clinical Nuclear Medicine.” AsbestosClaims.Law Library. https://asbestosclaims.law/library/research/journals/clinical-nuclear-medicine.

ACL Doc numbers and their short links never change. See how to cite the Library.

Talk with an asbestos lawyer

Start with what you remember, and we'll take it from there.

This page is provided for general informational purposes and does not constitute legal advice. Every asbestos case turns on its own facts, exposure history, diagnosis, deadlines, available evidence, and applicable law. Reviewing this page does not create an attorney-client relationship. For advice about your specific situation, call 833-4-ASBESTOS for a free case review.